

Resource Summary Report

Generated by PRECISE-TBI on Sep 17, 2026

Icahn School of Medicine at Mount Sinai Human Immune Monitoring Center Core Facility

RRID:SCR_027571

Type: Tool

Proper Citation

Icahn School of Medicine at Mount Sinai Human Immune Monitoring Center Core Facility (RRID:SCR_027571)

Resource Information

URL: <https://icahn.mssm.edu/research/human-immune-monitoring-center>

Proper Citation: Icahn School of Medicine at Mount Sinai Human Immune Monitoring Center Core Facility (RRID:SCR_027571)

Description: Core provides team of experts in the characterization of immune profiles and treatment responses across a diverse range of diseases, such as cancer, autoimmunity, allergy, and neuro-immune disorders. Offers equipment in the field for research at Genomic, cellular and proteomic analysis. Develops assays to balance innovation with protocols and operating procedures to ensure data quality and reproducibility.

Synonyms: , Icahn School of Medicine at Mount Sinai Mount Sinai Human Immune Monitoring Center, Mount Sinai Human Immune Monitoring Center

Resource Type: access service resource, core facility, service resource

Keywords: ABRF, characterization of immune profiles and treatment responses, equipment, assays

Resource Name: Icahn School of Medicine at Mount Sinai Human Immune Monitoring Center Core Facility

Resource ID: SCR_027571

Alternate IDs: ABRF_5607

Alternate URLs: <https://https://coremarketplace.org/?FacilityID=5607&citation=1>

Record Creation Time: 20251021T055515+0000

Record Last Update: 20260912T200530+0000

Ratings and Alerts

No rating or validation information has been found for Icahn School of Medicine at Mount Sinai Human Immune Monitoring Center Core Facility.

No alerts have been found for Icahn School of Medicine at Mount Sinai Human Immune Monitoring Center Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Li Z, et al. (2026) Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(14), 2911.

Cohen LJ, et al. (2022) Unraveling function and diversity of bacterial lectins in the human microbiome. Nature communications, 13(1), 3101.